Aurobindo Pharma earnings under pressure due to muted performance in US, Europe
The US sales that contributed more than half to total formulation sales, declined 11.1% year-on-year during the September quarter, while the European formulation sales declined 8.8% year-on-year
Aurobindo Pharma’s stock hit a 52-week low on the National Stock Exchange on 14 November, and continues to trade near those levels. The stock is currently down almost 35% year-to-date following the company’s performance in the September quarter.
Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!Let’s get started
Login to enjoy exclusive benefits!
- Unlocked premium articles
- Personalized news
- Market Watchlist
- Insightful Newsletters & more